Skip to main content

Table 1 Clinical characteristics and metabolic measurements in plasma and adipose tissue of the subjects participating in the study.

From: Differential alterations of the concentrations of endocannabinoids and related lipids in the subcutaneous adipose tissue of obese diabetic patients

  Diabetes + obesity Obesity Control
Males (n) 10 11 8
Age (years) 47 [8] 47 [20] 38 [9]
BMI (kg/m2) 33.4 [2.4] ** 34.5 [2.7] ** 23.8 [1.2]
Waist circumference (cm) 111.4 [7.7] ** 113.1 [6.7] ** 84.9 [4.4]
Plasma cholesterol (mg/dl) 171.8 [25.9] 194.1 [29.9] 166.7 [24.2]
Plasma triglyceride (mg/dl) 111.2 [54.7] 99.8 [34.7] 72.4 [28.2]
LDL cholesterol (mg/dl) 102.1 [19.6] 114.9 [26.4] 96.8 [14.6]
HDL cholesterol (mg/dl) 34.5 [5.8] *§ 44.3 [10.3] 47.7 [10.6]
Plasma glucose (mg/dl) 132.7 [37.2] *§ 87.9 [13.9] 87.2 [9.9]
Plasma insulin (mU/l) 14.3 [6.4] 15.6 [4.2] 6.4 [1.5]
Plasma leptin (ng/ml) 9.4 [4.2]§ 24.9 [9.6]** 5.4 [2.3]
Adipose tissue leptin mRNA (AU) 2.62 [1.90] * 1.73 [1.82] 0.77 [0.38]
Adipose tissue LPL activity
(nmol fatty acids/g tissue)
105 [45] *§ 231 [128] 251 [119]
Insulin sensitivity (M-value) (mg/kg/min) 4.55 [1.41] ** 4.63 [1.48] ** 8.13 [2.32]
FFA during hyperinsulinaemic clamp (μmol/l) 84.0 [50.8] * 73.0 [33.7] * 36.2 [7.4]
  1. Data are expressed as M [SD]. ANOVA and LSD (Kruskal-Wallis for plasma triglyceride, LPL activity, and leptin RNA) * p < 0.05, ** p < 0.001 vs Control, §p < 0.05 vs Obesity. AU = arbitrary units, LPL = lipoprotein lipase.